A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Phase 1
Terminated
- Conditions
- Pancreatic Ductal CancerColorectal CancerAdvanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT06194877
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorB-Raf Mutation-Related Tumors
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT04249843
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Beverly Hills, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath